1 |
Iwata, N., Takaki, Y., Fukami, S., Tsubuki, S., and Saido, T. C. (2002). Region-specific reduction of A -degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J. Neurosci. Res. 70, 493-500
DOI
ScienceOn
|
2 |
Lu, B., Gerard, N. P., Kolakowski, L. F. Jr., Bozza, M., Zurakowski, D., Finco, O., Carroll, M. C., and Gerard, C. (1995). Neutral endopeptidase modulation of septic shock. J. Exp. Med. 181, 2271-2275
DOI
|
3 |
Tumer, A. J., Issac, R. E., and Coates, D. (2001). The neprilysin (NEP) family of zinc metalloendopeptidase genomics and function. Bioassays. 23, 261-269
DOI
ScienceOn
|
4 |
Hwang, D. Y., Chae, K. R., Kang, T. S., Hwang, J. H., Lim, C. H., Kang, H. K., Goo, J. S., Lee, M. R., Lim, H. J., Min, S. H., Cho, J. Y., Hong, J. T., Song, C. W., Paik, S. G., Cho, J. S., and Kim, Y. K. (2002). Alterations in behavior, amyloid -42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease. FASEB J. 16, 805-813
DOI
ScienceOn
|
5 |
Akiyama, H., Kondo, H., Ikeda, K., Kato, M., and McGeer, P. L. (2001). Immunohistochemical localization of neprilysis in the human cerebral cortex: inverse association with vulnerability to amyloid -protein (A ) deposition. Brain Res. 902, 277-281
DOI
ScienceOn
|
6 |
Yasojima, K., McGeer, E. G., and McGeer, P. L. (2001b). Relationship between -amyloid peptide generating molecules and neprilysin in Alzheimer's disease and normal brain. Brain Res. 919, 115-121
DOI
ScienceOn
|
7 |
Apelt, J., Ach, K., and Schliebs, R. (2003). Aging-related downregulation of neprilysin, a putative -amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of -amyloid plaques. Neuroscu. Lett. 339, 183-186
DOI
ScienceOn
|
8 |
Glabe, C. (2000). Does Alzheimer disease tilt the scales of amyloid degradation versus accumulation? Nat. med. 6, 133-134
DOI
ScienceOn
|
9 |
Hwang, D. Y., Cho, J. S., Lee, S. H., Chae, K. R., Lim, H. J., Min, S. H., Seo, S. J., Song, Y. S., Song, C. W., Paik, S. K., Sheen, Y. Y., and Kim, Y. K. (2004). Aberrant expressions of pathogenic phenptype in Alzheimer's diseased transgenic mice carrying NSE-controlled APPsw. Exp. Neurol. 186, 20-3
DOI
ScienceOn
|
10 |
Gomez-Isla, T., Price, J. L., MaKeel, D. W., Morris, J. C., Growdon, J. H., and Hyman, B. T. (1996). Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 16, 4491-4500
DOI
|
11 |
Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoli, E., Kawashima-Morishima, M., Lee, H. J., Hama, E., Sekine-Aizawa, Y., and Saido, T. C. (2000). Identification of the major A -42 degrading catabolic pathway in brain parenchyma suppression leads to biochemical and pathological deposition. Nat. Med. 6, 143-150
DOI
ScienceOn
|
12 |
Mohajeri, M., Wollmer, M. A., and Nitsch, R. M. (2002). A -42induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo. J. Biol. Chem. 277, 35460-35465
DOI
ScienceOn
|
13 |
Lu, B., Gerard, N. P., Kolakowski, L. F. Jr., Finco, O., Carroll, M. C., and Gerard, M. C. (1996). Neutral endopeptidase modulates septic shock. Ann. N.Y. Acad. Sci. 780, 156-163
DOI
ScienceOn
|
14 |
Yasojima, K., Akiyama, H., McGeer, E. G., and McGeer, P. L. (2001a) Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship in deficient degradation of amyloid peptide. Neurosci. Lett. 297, 97-100
DOI
ScienceOn
|